Colistin-Reference-Cited by-同舟云学术

Colistin

Published:2013-07-10 Issue:8 Volume:54 Page:936-944
ISSN:0020-9554
Container-title:Der Internist
language:de
Short-container-title:Internist

Author:

Stocker H.,Kern W.V.

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00108-012-3141-3.pdf

Reference36 articles.

1. Bergen PJ, Bulitta JB, Forrest A et al (2010) Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54:3783–3789

2. Bergen PJ, Li J, Rayner CR et al (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953–1958

3. Betrosian AP, Frantzeskaki F, Xanthaki A et al (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56:432–436

4. Brink AJ, Coetzee J, Corcoran C et al (2013) Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol 51:369–372

5. Chen G, Thamlikitkul V, Jacob J et al (2011) Plasma protein binding of colistin in critically-ill patients receiving intravenous colistin methanesulfonate. 51st ICAAC. Chicago, USA

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intensivtherapie bei Pneumonien;Springer Reference Medizin;2024

2. Professionelle Pflege in der Infektionsprävention;ProCare;2023-12

3. Intensivtherapie bei Pneumonien;Die Intensivmedizin;2022

4. Neue Antibiotika bei schweren Infektionen durch multiresistente Erreger;Der Anaesthesist;2019-09-25

5. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations;PLOS ONE;2018-04-12